BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, May 3, 2024
See today's BioWorld
Home
» Immupharma rises on start of pivotal trial of lupus drug Lupuzor
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immupharma rises on start of pivotal trial of lupus drug Lupuzor
Jan. 23, 2015
By
Cormac Sheridan
No Comments
DUBLIN – Shares in Immupharma plc traded as high as 31 percent Thursday on news that immunomodulatory peptide Lupuzor (IPP-201101) is, after a lengthy delay, finally entering a pivotal phase III trial in systemic lupus erythematosus (SLE).
BioWorld